Last reviewed · How we verify

NCT06932354: MeCool

Metabolic Monitoring During Therapeutic Hypothermia (Cooling) for Hypoxic Ischaemic Encephalopathy

Completed NA Last updated 17 April 2025
What this trial tests

NA trial testing CGM in Hypoxic-Ischemic Encephalopathy in 16 participants. Completed in 31 December 2024.

Timeline
10 May 2019
Primary endpoint
1 December 2022
31 December 2024

Quick facts

Lead sponsorKathryn Beardsall
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment16
Start date10 May 2019
Primary completion1 December 2022
Estimated completion31 December 2024
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Kathryn Beardsall

Who can join

Under 2 Days, any sex, with Hypoxic-Ischemic Encephalopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine if CGM can be safely used in these babies, and to use this alongside innovative methods to measure alternative fuels to optimise care of these vulnerable babies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of CGM

Trials testing the same drug.

Other recruiting trials for Hypoxic-Ischemic Encephalopathy

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06932354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing